West Pharmaceutical Services, Inc. (WST) fair value analysis
S&P 500 · Updated 2026-10-19
WST price how computed
Forward Fair Value verdict
Fairly valuedWST is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $366.00
- Sector
- Healthcare
- 12-month range
- $230.95–$384.02
- Market cap
- $25.8B
- From 52-week high
- -4.7%
- Shares outstanding
- 70.4M
- Rank in Healthcare by discount to fair value
- #60 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
West Pharmaceutical Services, Inc. is a manufacturer of packaging and delivery systems for injectable drugs and healthcare products, serving pharmaceutical and healthcare companies globally. The company operates manufacturing facilities and distribution centers across North America, Europe, Asia, and other regions worldwide.
WST currently ranks #60 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $25.8B
- P/E (trailing)
- 43x
- Revenue (TTM)
- $3.33B
- Net margin
- 17.0%
- EPS (TTM)
- $8.50
- Gross margin
- 37.7%
- Debt / equity
- 0.10
- Revenue growth (3-yr avg)
- 5.6%
- Shares outstanding
- 70.4M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 63 · neutral
- 50-day average
- $358.14
- 200-day average
- $307.29
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $0.88 per share (4 payments)
- Yield on last price
- 0.24%
- Consecutive years of increases
- 11
- Last ex-dividend date
- 2026-07-29
- Last payment date
- 2026-08-05
Earnings how computed
- Next earnings report
- 2026-10-29 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+13.9%)
2026-03 ▲ beat (+26.8%)
2025-12 ▲ beat (+11.5%)
2025-09 ▲ beat (+14.6%)
2025-06 ▲ beat (+19.5%)
2025-03 ▲ beat (+15.1%)
2024-12 ▲ beat (+6.4%)
2024-09 ▲ beat (+24.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 16 buy · 1 hold · 0 sell (17 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $413
- Target vs last price
- +12.8%
What our data shows for WST
- Our model validated 17 trailing price-to-earnings windows for WST, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $230.95–$384.02.
- The 14-day relative strength index sits at a neutral 63.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for WST
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent WST news
TickrTrends' derived news-sentiment signal for WST is currently leaning positive, computed from recent coverage.
- West Pharmaceutical Services (WST) Raises Quarterly Dividend by 18.2% (gurufocus.com, 2026-10-20)
TickrTrends take: West Pharmaceutical Services increased its quarterly dividend, which typically reflects management confidence in the company's cash generation and financial position. For investors focused on valuation, a dividend increase of this magnitude warrants attention to whether the company can sustain higher shareholder returns while maintaining its current valuation multiple relative to peers in the Healthcare sector. TickrTrends currently views WST as fairly valued, so monitoring whether this dividend policy shift signals changing capital allocation priorities or underlying business momentum will be important for assessing whether that valuation assessment remains appropriate. - WST Maintains Buy Rating -- Price Target Raised to $420 by TD Cowen (gurufocus.com, 2026-10-13)
TickrTrends take: WST's maintenance of a buy rating with an elevated price target from TD Cowen provides context for evaluating whether the Fairly valued assessment aligns with analyst expectations in the Healthcare sector. A valuation-focused reader should monitor whether this analyst action reflects confidence in fundamental performance or represents a gap between current market pricing and the higher target, which could signal either near-term upside potential or a divergence from intrinsic value estimates. The persistence of buy-side sentiment at a raised target suggests analysts see catalysts ahead, though this should be weighed against TickrTrends' current valuation stance. - West Pharmaceutical Services Needs Faster Earnings Growth To Justify Its Price (NYSE:WST) (seekingalpha.com, 2026-10-08)
TickrTrends take: West Pharmaceutical Services operates in the Healthcare sector and is currently assessed as fairly valued by TickrTrends. The headline suggests that the market has priced in expectations for earnings growth that the company may need to demonstrate going forward. Investors focused on valuation metrics should monitor whether WST's earnings growth trajectory can sustain or improve relative to its current stock price to maintain this fair value assessment.
More WST news
- West Pharma Stock: Still A Buy, But Expectations Are Rising (NYSE:WST) (seekingalpha.com, 2026-10-07)
- Is West Pharmaceutical Services Inc (WST) Overvalued After 3.2% Rally? GF Value Says Overvalued (gurufocus.com, 2026-10-05)
What people are saying
Follow the WST conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for WST showed improvement this week, with the quality grade advancing from B to A while the current valuation verdict remains Fairly valued. This upgrade in quality metrics reflects strengthening fundamentals within the Healthcare sector stock.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for WST show movement in the healthcare sector rankings this week. The stock's sector discount rank declined from 67 to 73, indicating a relative shift in its valuation positioning within the healthcare sector. WST currently carries a fairly valued verdict according to the analysis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is WST stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), WST is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is WST's TickrTrends verdict?
WST's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does WST compare to other Healthcare stocks?
WST ranks #60 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is WST overbought or oversold?
WST's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does WST pay a dividend?
Yes. WST paid $0.88 per share over the last twelve months (4 payments), a 0.24% yield on TickrTrends' last price, and has raised the annual total for 11 consecutive years. The last ex-dividend date was 2026-07-29.
When does WST report earnings next?
WST's next earnings report is scheduled for 2026-10-29 (pre-market), per the published earnings calendar.
Does WST usually beat earnings estimates?
Over its last 8 reported quarters WST beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about WST?
Of 17 analysts covering WST, 16 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $413 (+12.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
WST vs A · WST vs ACHC · WST vs AVAH · WST vs COR · WST vs CVS